FRA:HPHA • DE000A11QVV0
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for HEIDELBERG PHARMA AG (HPHA.DE).
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 18.514M 958.06% | 9.859M -46.75% | 6.849M -30.53% | 9.18M 34.03% | 10.2M 11.11% | 13.26M 30.00% | |
| EBITDA YoY % growth | -17.503M 30.35% | -20.423M -16.69% | -22.98M -12.52% | -29.376M -27.83% | -13.311M 54.69% | -8.262M 37.93% | |
| EBIT YoY % growth | -18.26M 29.59% | -21.302M -16.66% | -23.852M -11.97% | -30.192M -26.58% | -13.821M 54.22% | -9.894M 28.41% | |
| Operating Margin | -98.63% | -216.07% | -348.23% | -328.89% | -135.50% | -74.62% | |
| EPS YoY % growth | N/A 10.49% | N/A -12.50% | N/A 40.28% | -0.63 -44.19% | -0.30 53.23% | -0.20 31.03% |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
8 analysts have analysed HPHA.DE and the average price target is 5.61 EUR. This implies a price increase of 96.84% is expected in the next year compared to the current price of 2.85.
The number of analysts covering HEIDELBERG PHARMA AG (HPHA.DE) is 8.